Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > It does not make a lot of sense

<< Previous

Bullboard Posts

Next >>

Post by Duster340on Mar 26, 2024 9:27am

367 Views

Post# 35952651

It does not make a lot of sense

that nuance would burn through there own cash to let antibe carry on with the P2 trials. what if the drug is unsuccessful? the burden of bringing the drug to a point where there would be potential partners or to a point were they could have got a financing deal was squandered by a poorly run company. nuance has got antibe over the barrel, if for some reason they were to throw out a life line it will not favor antibe or it's share holders.
glta

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments